CTOs on the Move

Syantra

www.syantra.com

 
With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.syantra.com
  • 105 - 32 Royal Vista Drive NW
    Calgary, AB CAN T3R 0H9
  • Phone: 877.331.0516

Executives

Name Title Contact Details

Similar Companies

Fluke Biomedical

Fluke Biomedical Corp. is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Labquip

Labquip Ltd is a Woodbridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DBV Technologies

DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV`s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.

Thallion Pharmaceuticals

Thallion Pharmaceuticals is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Obsidian Therapeutics

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian`s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we`re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the heart of Cambridge, we`re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.